[account_shop_links]
Primer: Biosimilars in the US Oncology Market
$880.00 – $1,760.00
Licensing Options
- SINGLE-USER LICENSE
A Single-User License allows access to an individual user.
- ENTERPRISE-WIDE LICENSE
An Enterprise-Wide License allows access to all employees and sites within an organization.
Report Overview
Biosimilars have come to the forefront of discussion within healthcare partly because of their potential to reduce healthcare costs. Furthermore, the potential for approval of Biosimilars exists under the Patient Protection and Affordable Care Act (PPACA), for which the US Food and Drug Administration (FDA) is expected to release general guidance this year.
What you will learn:
- Oncologists’ familiarity with Biosimilars and what their top-line concerns are.
- Oncologists’ concerns about safety, as well as preferred primary endpoints in a newly launched Biosimilars product.
- Oncologists’ views surrounding their expectations for Biosimilar pricing and prescribing behavior, and payer reimbursement expectations.
Report Contents:
- Awareness of Biosimilars among US Oncologists
- Datapoints/Evidence for evaluating Biosimilars
- Manufacturing of Biosimilars
- Potential benefits of Biosimilars to practices and to patients
- Pricing, prescribing, and reimbursement
